Molecular and Clinical Aspects of Pseudohypoparathyroidism

The Parathyroids: Basic and Clinical Concepts: Third Edition

Volumn , Issue , 2015, Pages 781-805

  Levine, Michael A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Adenylyl cyclase; G proteins; Imprinting; Pseudohypoparathyroidism; PTH resistance

Indexed keywords

EID: 84942768414     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397166-1.00055-2     Document Type: Chapter

References (270)

1. Albright F., Burnett C.H., Smith P.H. Pseudohypoparathyroidism: an example of "Seabright-Bantam syndrome.". Endocrinology 1942, 30:922-932.
2. Chase L.R., Melson G.L., Aurbach G.D. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969, 48:1832-1844.
3. George F.W., Wilson J.D. Pathogenesis of the henny feathering trait in the Sebright bantam chicken. Increased conversion of androgen to estrogen in skin. J Clin Invest 1980, 66:57-65.
4. Mann J.B., Alterman S., Hills A.G. Albright's hereditary osteodystrophy comprising pseudohypoparathyroidism and pseudo-pseudohypoparathyroidism with a report of two cases representing the complete syndrome occuring in successive generations. Ann Intern Med 1962, 56:315-342.
5. Albright F., Forbes A.P., Henneman P.H. Pseudopseudohypoparathyroidism. Trans Assoc Am Phys 1952, 65:337-350.
6. Fitch N. Albright's hereditary osteodystrophy: a review. Am J Med Genet 1982, 11:11-29.
7. Winter J.S.D., Hughes I.A. Familial pseudohypoparathyroidism without somatic anomalies. Can Med Assoc J 1980, 123:26-31.
8. Levine M.A., Downs R.W., Singer M.J., Marx S.J., Aurbach G.D., Spiegel A.M. Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem Biophys Res Commun 1980, 94:1319-1324.
9. Farfel Z., Brickman A.S., Kaslow H.R., Brothers V.M., Bourne H.R. Defect of receptor-cyclase coupling protein in pseudohypoparathyroidism. N Engl J Med 1980, 303:237-242.
10. Linglart A., Carel J.C., Garabedian M., Le T., Mallet E., Kottler M.L. GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J Clin Endocrinol Metab 2002, 87:189-197.
11. Thiele S., de Sanctis L., Werner R., Grotzinger J., Aydin C., Juppner H., et al. Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type Ic defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsalpha-receptor interaction. Hum Mutat 2011, 32:653-660.
12. Bell N.H., Avery S., Sinha T., Clark C.M., Allen D.O., Johnston C. Effects of dibutyryl cyclic adenosine 3',5'-monophosphate and parathyroid extract on calcium and phosphorous metabolism in hypoparathyroidism and pseudohypoparathyroidism. J Clin Invest 1972, 51:816-823.
13. Drezner M.K., Neelon F.A., Lebovitz H.E. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973, 280:1056-1060.
14. Silve C., Le-Stunff C., Motte E., Gunes Y., Linglart A., Clauser E. Acrodysostosis syndromes. Bonekey Rep 2012, 1:225.
15. Shore E.M., Ahn J., Jan de Beur S., Li M., Xu M., Gardner R.J., et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002, 346:99-106.
16. Lau K., Willig R.P., Hiort O., Hoeger P.H. Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. Clin Exp Dermatol 2012, 37:646-648.
17. Martin J., Tucker M., Browning J.C. Infantile osteoma cutis as a presentation of a GNAS mutation. Pediatr Dermatol 2012, 29:483-484.
18. Ward S., Sugo E., Verge C.F., Wargon O. Three cases of osteoma cutis occurring in infancy. A brief overview of osteoma cutis and its association with pseudo-pseudohypoparathyroidism. Australas J Dermatol 2011, 52:127-131.
19. Rao D.S., Parfitt A.M., Kleerekoper M., Pumo B.S., Frame B. Dissociation between the effects of endogenous parathyroid hormone on adenosine 3',5'-monophosphate generation and phosphate reabsorption in hypocalcemia due to vitamin D depletion: an acquired disorder resembling pseudohypoparathyroidism type II. J Clin Endocrinol Metab 1985, 61:285-290.
20. Linglart A., Fryssira H., Hiort O., Holterhus P.M., Perez de Nanclares G., Argente J., et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab 2012, 97:E2328-E2338.
21. Usdin T.B., Wang T., Hoare S.R., Mezey E., Palkovits M. New members of the parathyroid hormone/parathyroid hormone receptor family: the parathyroid hormone 2 receptor and tuberoinfundibular peptide of 39 residues. Front Neuroendocrinol 2000, 21:349-383.
22. Usdin T.B., Bonner T.I., Hoare S.R. The parathyroid hormone 2 (PTH2) receptor. Receptors Channels 2002, 8:211-218.
23. Dobolyi A., Palkovits M., Usdin T.B. The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol 2010, 90:29-59.
24. Piserchio A., Usdin T., Mierke D.F. Structure of tuberoinfundibular peptide of 39 residues. J Biol Chem 2000, 275:27284-27290.
25. Clark J.A., Bonner T.I., Kim A.S., Usdin T.B. Multiple regions of ligand discrimination revealed by analysis of chimeric parathyroid hormone 2 (PTH2) and PTH/PTH-related peptide (PTHrP) receptors. Mol Endocrinol 1998, 12:193-206.
26. Hoare S.R., Clark J.A., Usdin T.B. Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity. J Biol Chem 2000, 275:27274-27283.
27. Hoare S.R., Rubin D.A., Juppner H., Usdin T.B. Evaluating the ligand specificity of zebrafish parathyroid hormone (PTH) receptors: comparison of PTH, PTH-related protein, and tuberoinfundibular peptide of 39 residues. Endocrinology 2000, 141:3080-3086.
28. Rubin D.A., Juppner H. Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide. J Biol Chem 1999, 274:28185-28190.
29. Gensure R.C., Ponugoti B., Gunes Y., Papasani M.R., Lanske B., Bastepe M., et al. Identification and characterization of two parathyroid hormone-like molecules in zebrafish. Endocrinology 2004, 145:1634-1639.
30. Holinstat M., Oldham W.M., Hamm H.E. G-protein-coupled receptors: evolving views on physiological signalling: symposium on G-protein-coupled receptors: evolving concepts and new techniques. EMBO Rep 2006, 7:866-869.
31. Bohm A., Gaudet R., Sigler P.B. Structural aspects of heterotrimeric G-protein signaling. Curr Opin Biotechnol 1997, 8:480-487.
32. Oldham W.M., Hamm H.E. Structural basis of function in heterotrimeric G proteins. Q Rev Biophys 2006, 39:117-166.
33. Van Eps N., Oldham W.M., Hamm H.E., Hubbell W.L. Structural and dynamical changes in an alpha-subunit of a heterotrimeric G protein along the activation pathway. Proc Natl Acad Sci USA 2006, 103:16194-16199.
34. Schmidt C.J., Neer E.J. In vitro synthesis of G protein beta gamma dimers. J Biol Chem 1991, 266:4538-4544.
35. Schmidt C.J., Thomas T.C., Levine M.A., Neer E.J. Specificity of G protein beta and gamma subunit interactions. J Biol Chem 1992, 267:13807-13810.
36. Rahmatullah M., Robishaw J.D. Direct interaction of the α and g subunits of the G proteins. J Biol Chem 1994, 269:3574-3580.
37. Rahmatullah M., Ginnan R., Robishaw J.D. Specificity of G protein alpha-gamma subunit interactions. N- terminal 15 amino acids of gamma subunit specifies interaction with alpha subunit. J Biol Chem 1995, 270:2946-2951.
38. Taussig R., Zimmermann G. Type-specific regulation of mammalian adenylyl cyclases by G protein pathways. Adv Second Messenger Phosphoprotein Res 1998, 32:81-98.
39. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 1998, 80:231-264.
40. Sprang S.R., Chen Z., Du X. Structural basis of effector regulation and signal termination in heterotrimeric Galpha proteins. Adv Protein Chem 2007, 74:1-65.
41. Ross E.M., Wang J., Tu Y., Biddlecome G.H. Guanosinetriphosphatase-activating proteins for heterotrimeric G-proteins. Adv Pharmacol 1998, 42:458-461.
42. Bhatt B., Burns J., Flanner D., McGee J. Direct visualization of single copy genes on banded metaphase chromosomes by nonisotopic in situ hybridization. Nucleic Acids Res 1988, 16:3951-3961.
43. Boyajian C.L., Cooper D.M. Potent and cooperative feedback inhibition of adenylate cyclase activity by calcium in pituitary-derived GH3 cells. Cell Calcium 1990, 11:299-307.
44. Jones D.T., Masters S.B., Bourne H.R., Reed R.R. Biochemical characterization of three stimulatory GTP-binding proteins. J Biol Chem 1990, 265:2671-2676.
45. Graziano M.P., Freissmuth M., Gilman A.G. Expression of Gs alpha in Escherichia coli. Purification and properties of two forms of the protein. J Biol Chem 1989, 264:409-418.
46. Novotny J., Svoboda P. The long (Gs(alpha)-L) and short (Gs(alpha)-S) variants of the stimulatory guanine nucleotide-binding protein. Do they behave in an identical way?. J Mol Endocrinol 1998, 20:163-173.
47. Liu Z., Segawa H., Aydin C., Reyes M., Erben R.G., Weinstein L.S., et al. Transgenic overexpression of the extra-large Gsalpha variant XLalphas enhances Gsalpha-mediated responses in the mouse renal proximal tubule in vivo. Endocrinology 2011, 152:1222-1233.
48. Plagge A., Gordon E., Dean W., Boiani R., Cinti S., Peters J., et al. The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding. Nat Genet 2004, 36:818-826.
49. Xie T., Plagge A., Gavrilova O., Pack S., Jou W., Lai E.W., et al. The alternative stimulatory G protein alpha-subunit XLalphas is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem 2006, 281:18989-18999.
50. Eaton S.A., Williamson C.M., Ball S.T., Beechey C.V., Moir L., Edwards J., et al. New mutations at the imprinted Gnas cluster show gene dosage effects of Gsalpha in postnatal growth and implicate XLalphas in bone and fat metabolism but not in suckling. Mol Cell Biol 2012, 32:1017-1029.
51. Puzhko S., Goodyer C.G., Kerachian M.A., Canaff L., Misra M., Juppner H., et al. Parathyroid hormone signaling via Galphas is selectively inhibited by an NH(2)-terminally truncated Galphas: implications for pseudohypoparathyroidism. J Bone Miner Res 2011, 26:2473-2485.
52. Coombes C., Arnaud P., Gordon E., Dean W., Coar E.A., Williamson C.M., et al. Epigenetic properties and identification of an imprint mark in the Nesp-Gnasxl domain of the mouse Gnas imprinted locus. Mol Cell Biol 2003, 23:5475-5488.
53. Liu J., Litman D., Rosenberg M.J., Yu S., Biesecker L.G., Weinstein L.S. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. J Clin Invest 2000, 106:1167-1174.
54. Bastepe M., Frohlich L.F., Hendy G.N., Indridason O.S., Josse R.G., Koshiyama H., et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003, 112:1255-1263.
55. Bastepe M., Frohlich L.F., Linglart A., Abu-Zahra H.S., Tojo K., Ward L.M., et al. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 2005, 37:25-27.
56. Chillambhi S., Turan S., Hwang D.Y., Chen H.C., Juppner H., Bastepe M. Deletion of the noncoding GNAS antisense transcript causes pseudohypoparathyroidism type Ib and biparental defects of GNAS methylation in cis. J Clin Endocrinol Metab 2010, 95:3993-4002.
57. Richard N., Abeguile G., Coudray N., Mittre H., Gruchy N., Andrieux J., et al. A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal dominant pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2012, 97:E863-E867.
58. Linglart A., Gensure R.C., Olney R.C., Juppner H., Bastepe M. A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am J Hum Genet 2005, 76:804-814.
59. Bastepe M., Lane A.H., Juppner H. Paternal uniparental isodisomy of chromosome 20q-and the resulting changes in GNAS1 methylation-as a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 2001, 68:1283-1289.
60. Hayward B.E., Kamiya M., Strain L., Moran V., Campbell R., Hayashizaki Y., et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci USA 1998, 95:10038-10043.
61. Hayward B.E., Moran V., Strain L., Bonthron D.T. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci USA 1998, 95:15475-15480.
62. Campbell R., Gosden C.M., Bonthron D.T. Parental origin of transcription from the human GNAS1 gene. J Med Genet 1994, 31:607-614.
63. Crane J.L., Shamblott M.J., Axelman J., Hsu S., Levine M.A., Germain-Lee E.L. Imprinting status of Galpha(s), NESP55, and XLalphas in cell cultures derived from human embryonic germ cells: GNAS imprinting in human embryonic germ cells. Clin Transl Sci 2009, 2:355-360.
64. Crane J.K., Hewlett E.L., Weikel C.S. Failure of pertussis toxin to inhibit activation of guanylate cyclase by the heat-stable enterotoxin of Escherichia coli (STa) in the T84 cell line. Infect Immun 1989, 57:1186-1191.
65. Turan S., Fernandez-Rebollo E., Aydin C., Zoto T., Reyes M., Bounoutas G., et al. Postnatal establishment of allelic galphas silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous galphas disruption. J Bone Miner Res 2014, 29:749-760.
66. Shore E.M., Li M., Jan de Beur S.M., Hebela N., Eddy M.C., Whyte M.P., et al. Mutations in the gene encoding the stimulatory G protein of adenylyl cyclase in progressive osseous heteroplasia. J Bone Miner Res 1999, 14:s342.
67. Miric A., Vechio J.D., Levine M.A. Heterogeneous mutations in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 1993, 76:1560-1568.
68. Levis M.J., Bourne H.R. Activation of the alpha subunit of Gs in intact cells alters its abundance, rate of degradation, and membrane avidity. J Cell Biol 1992, 119:1297-1307.
69. Levine M.A. Pseudohypoparathyroidism. Principles of Bone Biology 1996, 853-876. Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
70. Yu S., Yu D., Lee E., Eckhaus M., Lee R., Corria Z., et al. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci USA 1998, 95:8715-8720.
71. Schwindinger W.F., Lawler A.M., Gearhart J.D., Levine M.A. A murine model of Albright hereditary osteodystrophy 1998, Endocrine Society, New Orleans, 480.
72. Castrop H., Oppermann M., Mizel D., Huang Y., Faulhaber-Walter R., Weiss Y., et al. Skeletal abnormalities and extra-skeletal ossification in mice with restricted Gsalpha deletion caused by a renin promoter-Cre transgene. Cell Tissue Res 2007, 330:487-501.
73. Xie T., Chen M., Zhang Q.H., Ma Z., Weinstein L.S. Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc Natl Acad Sci USA 2007, 104:19601-19606.
74. Xie T., Chen M., Gavrilova O., Lai E.W., Liu J., Weinstein L.S. Severe obesity and insulin resistance due to deletion of the maternal Gsalpha allele is reversed by paternal deletion of the Gsalpha imprint control region. Endocrinology 2008, 149:2443-2450.
75. Wu J.Y., Purton L.E., Rodda S.J., Chen M., Weinstein L.S., McMahon A.P., et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways. Proc Natl Acad Sci USA 2008, 105:16976-16981.
76. Chen M., Feng H.Z., Gupta D., Kelleher J., Dickerson K.E., Wang J., et al. G(s)alpha deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching, and glucose intolerance without insulin resistance or deficiency. Am J Physiol Cell Physiol 2009, 296:C930-C940.
77. Chen M., Wang J., Dickerson K.E., Kelleher J., Xie T., Gupta D., et al. Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab 2009, 9:548-555.
78. Sakamoto A., Weinstein L.S., Plagge A., Eckhaus M., Kelsey G. GNAS haploinsufficiency leads to subcutaneous tumor formation with collagen and elastin deposition and calcification. Endocr Res 2009, 34:1-9.
79. Klenke S., Siffert W., Frey U.H. A novel aspect of GNAS imprinting: higher maternal expression of Galphas in human lymphoblasts, peripheral blood mononuclear cells, mammary adipose tissue, and heart. Mol Cell Endocrinol 2011, 341:63-70.
80. Mizunashi K., Furukawa Y., Sohn H.E., Miura R., Yumita S., Yoshinaga K. Heterogeneity of pseudohypoparathyroidism type I from the aspect of urinary excretion of calcium and serum levels of parathyroid hormone. Calcif Tissue Int 1990, 46:227-232.
81. Shima M., Nose O., Shimizu K., Seino Y., Yabuuchi H., Saito T. Multiple associated endocrine abnormalities in a patient with pseudohypoparathyroidism type 1a. Eur J Pediatr 1988, 147:536-538.
82. Stone M.D., Hosking D.J., Garcia-Himmelstine C., White D.A., Rosenblum D., Worth H.G. The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993, 14:727-735.
83. Biber J., Hernando N., Forster I., Murer H. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009, 458:39-52.
84. Guo J., Song L., Liu M., Segawa H., Miyamoto K., Bringhurst F.R., et al. Activation of a non-cAMP/PKA signaling pathway downstream of the PTH/PTHrP receptor is essential for a sustained hypophosphatemic response to PTH infusion in male mice. Endocrinology 2013, 154:1680-1689.
85. Bastepe M., Weinstein L.S., Ogata N., Kawaguchi H., Juppner H., Kronenberg H.M., et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci USA 2004, 101:14794-14799.
86. Sakamoto A., Chen M., Kobayashi T., Kronenberg H.M., Weinstein L.S. Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J Bone Miner Res 2005, 20:663-671.
87. Sakamoto A., Chen M., Nakamura T., Xie T., Karsenty G., Weinstein L.S. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J Biol Chem 2005, 280:21369-21375.
88. Murray T.M., Rao L.G., Wong M.M., Waddell J.P., McBroom R., Tam C.S., et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res 1993, 8:83-91.
89. Drezner M.K., Neelon F.A., Haussler M., McPherson H.T., Lebovitz H.E. 1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab 1976, 42:621-628.
90. Drezner M.K., Haussler M.R. Normocalcemic pseudohypoparathyroidism. Am J Med 1979, 66:503-508.
91. Collins M.T., Lindsay J.R., Jain A., Kelly M.H., Cutler C.M., Weinstein L.S., et al. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res 2005, 20:1944-1950.
92. Degtyarev M.Y., Spiegel A.M., Jones T.L. The G protein alpha s subunit incorporates [3H]palmitic acid and mutation of cysteine-3 prevents this modification. Biochemistry 1993, 32:8057-8061.
93. Lecumberri B., Fernandez-Rebollo E., Sentchordi L., Saavedra P., Bernal-Chico A., Pallardo L.F., et al. Coexistence of two different pseudohypoparathyroidism subtypes (Ia and Ib) in the same kindred with independent Gs{alpha} coding mutations and GNAS imprinting defects. J Med Genet 2010, 47:276-280.
94. Elli F.M., deSanctis L., Ceoloni B., Barbieri A.M., Bordogna P., Beck-Peccoz P., et al. Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. Hum Mutat 2013, 34:411-416.
95. Freson K., Izzi B., Labarque V., Van Helvoirt M., Thys C., Wittevrongel C., et al. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J Clin Endocrinol Metab 2008, 93:4851-4859.
96. Bellus G.A., Gaudenz K., Zackai E.H., Clarke L.A., Szabo J., Francomano C.A., et al. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 1996, 14:174-176.
97. Schwindinger W.F., Miric A., Zimmerman D., Levine M.A. A novel Gsα mutant in a patient with Albright hereditary osteodystrophy uncouples cell surface receptors from adenylyl cyclase. J Biol Chem 1994, 269:25387-25391.
98. Farfel Z., Iiri T., Shapira H., Roitman A., Mouallem M., Bourne H.R. Pseudohypoparathyroidism, a novel mutation in the betagamma-contact region of Gsalpha impairs receptor stimulation. J Biol Chem 1996, 271:19653-19655.
99. Warner D.R., Weng G., Yu S., Matalon R., Weinstein L.S. A novel mutation in the switch 3 region of Gsalpha in a patient with Albright hereditary osteodystrophy impairs GDP binding and receptor activation. J Biol Chem 1998, 273(37):23976-23983.
100. Kim U.J., Birren B.W., Slepak T., Mancino V., Boysen C., Kang H.L., et al. Construction and characterization of a human bacterial artificial chromosome library. Genomics 1996, 34:213-218.
101. Jan de Beur S.M., Deng Z., Ding C.L., Levine M.A. Amplification of the GC-rich exon 1 of GNAS1 and identification of three novel nonsense mutations in Albright's hereditary osteodystrophy. Endocr Soc 1998.
102. Weinstein L.S., Gejman P.V., de Mazancourt P., American N., Spiegel A.M. A heterozygous 4-bp deletion mutation in the G s α gene (GNAS1) in a patient with Albright hereditary osteodystrophy. Genomics 1992, 13:1319-1321.
103. Shapira H., Mouallem M., Shapiro M.S., Weisman Y., Farfel Z. Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. Hum Genet. 1996, 97:73-75.
104. Light D.B., McCann F.V., Keller T.M., Stanton B.A. Amiloride-sensitive cation channel in apical membrane of inner medullary collecting duct. Am J Physiol 1988, 255:F278-F286.
105. Fischer J.A., Egert F., Werder E., Born W. An inherited mutation associated with functional deficiency of the alpha-subunit of the guanine nucleotide-binding protein Gs in pseudo- and pseudo-pseudohypoparathyroidism. J Clin Endocrinol Metab 1998, 83:935-938.
106. Mitsui T., Nagasaki K., Takagi M., Narumi S., Ishii T., Hasegawa T. A family of pseudohypoparathyroidism type Ia with an 850-kb submicroscopic deletion encompassing the whole GNAS locus. Am J Med Genet 2012, 158A:261-264.
107. de Sanctis L., Romagnolo D., Olivero M., Buzi F., Maghnie M., Scire G., et al. Molecular analysis of the GNAS1 gene for the correct diagnosis of Albright hereditary osteodystrophy and pseudohypoparathyroidism. Pediatr Res 2003, 53:749-755.
108. Ahmed S.F., Dixon P.H., Bonthron D.T., Stirling H.F., Barr D.G., Kelnar C.J., et al. GNAS1 mutational analysis in pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1998, 49:525-531.
109. Yokoyama M., Takeda K., Iyota K., Okabayashi T., Hashimoto K.A. 4-base pair deletion mutation of Gs alpha gene in a Japanese patient with pseudohypoparathyroidism. J Endocrinol Invest 1996, 19:236-241.
110. Walden U., Weissortel R., Corria Z., Yu D., Weinstein L., Kruse K., et al. Stimulatory guanine nucleotide binding protein subunit 1 mutation in two siblings with pseudohypoparathyroidism type 1a and mother with pseudopseudohypoparathyroidism. Eur J Pediatr 1999, 158:200-203.
111. Nakamoto J.M., Sandstrom A.T., Brickman A.S., Christenson R.A., Van Dop C. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet 1998, 77:261-267.
112. Alblas J., van Etten I., Khanum A., Moolenaar W.H. C-terminal truncation of the neurokinin-2 receptor causes enhanced and sustained agonist-induced signaling. Role of receptor phosphorylation in signal attenuation. J Biol Chem 1995, 270:8944-8951.
113. Carter A., Bardin C., Collins R., Simons C., Bray P., Spiegel A. Reduced expression of multiple forms of the alpha subunit of the stimulatory GTP-binding protein in pseudohypoparathyroidism type Ia. Proc Natl Acad Sci USA 1987, 84:7266-7269.
114. Mallet E., Carayon P., Amr S., Brunelle P., Ducastelle T., Basuyau J.P., et al. Coupling defect of thyrotropin receptor and adenylate cyclase in a pseudohypoparathyroid patient. J Clin Endocrinol Metab 1982, 54:1028-1032.
115. Iiri T., Herzmark P., Nakamoto J.M., van Dop C., Bourne H.R. Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature 1994, 371:164-168.
116. Wu W.I., Schwindinger W.F., Aparicio L.F., Levine M.A. Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of Gαs: a cause of pseudohypoparathyroidism Type Ib. J Biol Chem 2001, 276:165-171.
117. Patten J.L., Johns D.R., Valle D., Eil C., Gruppuso P.A., Steele G., et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med 1990, 322:1412-1419.
118. Thiele S., Werner R., Ahrens W., Hoppe U., Marschke C., Staedt P., et al. A disruptive mutation in exon 3 of the GNAS gene with albright hereditary osteodystrophy, normocalcemic pseudohypoparathyroidism, and selective long transcript variant Gsalpha-L deficiency. J Clin Endocrinol Metab 2007, 92:1764-1768.
119. Mantovani G., de Sanctis L., Barbieri A.M., Elli F.M., Bollati V., Vaira V., et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab 2010, 95:651-658.
120. Mariot V., Maupetit-Mehouas S., Sinding C., Kottler M.L., Linglart A. A maternal epimutation of GNAS leads to Albright osteodystrophy and parathyroid hormone resistance. J Clin Endocrinol Metab 2008, 93:661-665.
121. Unluturk U., Harmanci A., Babaoglu M., Yasar U., Varli K., Bastepe M., et al. Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid. Am J Med Sci 2008, 336:84-90.
122. de Nanclares G.P., Fernandez-Rebollo E., Santin I., Garcia-Cuartero B., Gaztambide S., Menendez E., et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 2007, 92:2370-2373.
123. Sanchez J., Perera E., Jan de Beur S., Ding C., Dang A., Berkovitz G.D., et al. Madelung-like deformity in pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab 2011, 96:E1507-E1511.
124. Mantovani G., Bondioni S., Linglart A., Maghnie M., Cisternino M., Corbetta S., et al. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2007, 92:3738-3742.
125. Levine M.A., Downs R.W., Moses A.M., Breslau N.A., Marx S.J., Lasker R.D., et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983, 74:545-556.
126. Zazo C., Thiele S., Martin C., Fernandez-Rebollo E., Martinez-Indart L., Werner R., et al. Gsalpha activity is reduced in erythrocyte membranes of patients with psedohypoparathyroidism due to epigenetic alterations at the GNAS locus. J Bone Miner Res 2011, 26:1864-1870.
127. Kidd G.S., Schaaf M., Adler R.A., Lassman M.N., Wray H.L. Skeletal responsiveness in pseudohypoparathyroidism: a spectrum of clinical disease. Am J Med 1980, 68:772-781.
128. Izzi B., Van Geet C., Freson K. Recent advances in GNAS epigenetic research of pseudohypoparathyroidism. Curr Mol Med 2012, 12:566-573.
129. Mantovani G. Clinical review: pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab 2011, 96:3020-3030.
130. Mantovani G., Elli F.M., Spada A. GNAS epigenetic defects and pseudohypoparathyroidism: time for a new classification?. Horm Metab Res 2012, 44:716-723.
131. Maupetit-Mehouas S., Mariot V., Reynes C., Bertrand G., Feillet F., Carel J.C., et al. Quantification of the methylation at the GNAS locus identifies subtypes of sporadic pseudohypoparathyroidism type Ib. J Med Genet 2011, 48:55-63.
132. Yuno A., Usui T., Yambe Y., Higashi K., Ugi S., Shinoda J., et al. Genetic and epigenetic states of the GNAS complex in pseudohypoparathyroidism type Ib using methylation-specific multiplex ligation-dependent probe amplification assay. Eur J Endocrinol 2013, 168:169-175.
133. Elli F.M., de Sanctis L., Peverelli E., Bordogna P., Pivetta B., Miolo G., et al. Autosomal Dominant Pseudohypoparathyroidism type Ib: a novel inherited deletion ablating STX16 causes Loss of Imprinting at the A/B DMR. J Clin Endocrinol Metab 2014, 99:E724-E728.
134. Turan S., Ignatius J., Moilanen J.S., Kuismin O., Stewart H., Mann N.P., et al. De novo STX16 deletions: an infrequent cause of pseudohypoparathyroidism type Ib that should be excluded in sporadic cases. J Clin Endocrinol Metab 2012, 97:E2314-E2319.
135. Frohlich L.F., Bastepe M., Ozturk D., Abu-Zahra H., Juppner H. Lack of Gnas epigenetic changes and pseudohypoparathyroidism type Ib in mice with targeted disruption of syntaxin-16. Endocrinology 2007, 148:2925-2935.
136. Chotalia M., Smallwood S.A., Ruf N., Dawson C., Lucifero D., Frontera M., et al. Transcription is required for establishment of germline methylation marks at imprinted genes. Genes Dev 2009, 23:105-117.
137. Frohlich L.F., Mrakovcic M., Steinborn R., Chung U.I., Bastepe M., Juppner H. Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. Proc Natl Acad Sci USA 2010, 107:9275-9280.
138. Fernandez-Rebollo E., Perez dN., Lecumberri B., Turan S., Anda E., Perez-Nanclares G., et al. Exclusion of the GNAS locus in PHP-Ib patients with broad GNAS methylation changes: evidence for an autosomal recessive form of PHP-Ib?. J Bone Miner Res 2011, 26:1854-1863.
139. Jan de Beur S.M., Ding C., Germain-Lee E., Cho J., Maret A., Levine M.A. Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at GNAS1. Am J Hum Genet 2003, 73:314-322.
140. Liu J., Nealon J.G., Weinstein L.S. Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 2005, 14:95-102.
141. Fernandez-Rebollo E., Lecumberri B., Garin I., Arroyo J., Bernal-Chico A., Goni F., et al. New mechanisms involved in paternal 20q disomy associated with pseudohypoparathyroidism. Eur J Endocrinol 2010, 163:953-962.
142. Bastepe M., Altug-Teber O., Agarwal C., Oberfield S.E., Bonin M., Juppner H. Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone 2011, 48:659-662.
143. Dixit A., Chandler K.E., Lever M., Poole R.L., Bullman H., Mughal M.Z., et al. Pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q. J Clin Endocrinol Metab 2013, 98:E103-E108.
144. Bastepe M., Altug-Teber O., Agarwal C., Oberfield S.E., Bonin M., Juppner H. Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone 2011, 48:659-662.
145. Adegbite N.S., Xu M., Kaplan F.S., Shore E.M., Pignolo R.J. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet A 2008, 146A:1788-1796.
146. Eddy M.C., Jan de Beur S.M., Yandow S., McAlister W.H., Shore E.M., Kaplan F.S., et al. Deficiency of the α-subunit of the stimulatory G protein (Gsα) and severe extraskeletal ossification. J Bone Miner Res 2000, 15:2074-2083.
147. Marx S.J., Hershman J.M., Aurbach G.D. Thyroid dysfunction in pseudohypoparathyroidism. J Clin Endocrinol Metab 1971, 33:822-828.
148. Werder E.A., Illig R., Bernasconi S., Kind H., Prader A. Excessive thyrotropin-releasing hormone in pseudohypoparathyroidism. Pediatr Res 1975, 9:12-16.
149. Wolfsdorf J.I., Rosenfield R.L., Fang V.S., Kobayashi R., Razdan A.K., Kim M.H. Partial gonadotrophin-resistance in pseudohypoparathyroidism. Acta Endocrinol 1978, 88:321-328.
150. Escobar M.E., Gryngarten M., Domene H., Ropelato G., Lopez M.R., Bergada C. Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome. J Pediatr Adolesc Gynecol 1997, 10:147-151.
151. Weisman Y., Golander A., Spirer Z., Farfel Z. Pseudohypoparathyroidism type Ia presenting as congenital hypothyroidism. J Pediatr 1985, 107:413-415.
152. Altschul S.F., Gish W. Local alignment statistics. Methods Enzymol 1996, 266:460-480.
153. Liu J., Erlichman B., Weinstein L.S. The stimulatory G protein alpha-subunit Gs alpha is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 2003, 88:4336-4341.
154. Germain-Lee E.L., Ding C.L., Deng Z., Crane J.K., Saji M., Ringel M.D., et al. Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 2002, 296:62-72.
155. Mantovani G., Maghnie M., Weber G., De Menis E., Brunelli V., Cappa M., et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type 1a: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003, 88:4070-4074.
156. Germain-Lee E.L., Groman J., Crane J.L., Jan de Beur S.M., Levine M.A. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multi-hormone resistance. J Clin Endocrinol Metab 2003, 88:4059-4069.
157. Kaji M., Umeda K., Ashida M., Tajima T. A case of pseudohypoparathyroidism type la complicated with growth hormone deficiency: recovery of growth hormone secretion after vitamin D therapy. Eur J Pediatr 2001, 160:679-681.
158. Scott D.C., Hung W. Pseudohypoparathyroidism type Ia and growth hormone deficiency in two siblings. J Pediatr Endocrinol Metab 1995, 8:205-207.
159. Mantovani G., Ferrante E., Giavoli C., Linglart A., Cappa M., Cisternino M., et al. Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: first study on the effect on growth. J Clin Endocrinol Metab 2010, 95:5011-5017.
160. Kruse K. Delayed puberty in pseudohypoparathyroidism type-I (Php-I). Pediatr Res 1984, 18:1224.
161. Namnoum A.B., Merriam G.R., Moses A.M., Levine M.A. Reproductive dysfunction in women with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1998, 83:824-829.
162. de Sanctis C., Lala R., Matarazzo P., Andreo M., de Sanctis L. Pubertal development in patients with McCune-Albright syndrome or pseudohypoparathyroidism. J Pediatr Endocrinol Metab 2003, 16(Suppl. 2):293-296.
163. Downs R.W., Levine M.A., Drezner M.K., Burch W.M., Spiegel A.M. Deficient adenylate cyclase regulatory protein in renal membranes from a patient with pseudohypoparathyroidism. J Clin Invest 1983, 71:231-235.
164. Carlson H.E., Brickman A.S., Bottazzo C.F. Prolactin deficiency in pseudohypoparathyroidism. N Engl J Med 1977, 296:140-144.
165. Al Salameh A., Despert F., Kottler M.L., Linglart A., Carel J.C., Lecomte P. Resistance to epinephrine and hypersensitivity (hyperresponsiveness) to CB1 antagonists in a patient with pseudohypoparathyroidism type Ic. Eur J Endocrinol 2010, 162:819-824.
166. Dekelbab B.H., Aughton D.J., Levine M.A. Pseudohypoparathyroidism type 1A and morbid obesity in infancy. Endocr Pract 2009, 15:249-253.
167. Long D.N., McGuire S., Levine M.A., Weinstein L.S., Germain-Lee E.L. Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J Clin Endocrinol Metab 2007, 92:1073-1079.
168. Chen M., Nemechek N.M., Mema E., Wang J., Weinstein L.S. Effects of deficiency of the G protein Gsalpha on energy and glucose homeostasis. Eur J Pharmacol 2011, 660:119-124.
169. Germain-Lee E.L., Schwindinger W., Crane J.L., Zewdu R., Zweifel L.S., Wand G., et al. A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 2005, 146:4697-4709.
170. Chen M., Gavrilova O., Liu J., Xie T., Deng C., Nguyen A.T., et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc Natl Acad Sci USA 2005, 102:7386-7391.
171. Chen M., Haluzik M., Wolf N.J., Lorenzo J., Dietz K.R., Reitman M.L., et al. Increased insulin sensitivity in paternal Gnas knockout mice is associated with increased lipid clearance. Endocrinology 2004, 145:4094-4102.
172. Muniyappa R., Warren M.A., Zhao X., Aney S.C., Courville A.B., Chen K.Y., et al. Reduced insulin sensitivity in adults with pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2013, 98:E1796-E1801.
173. Shoemaker A.H., Lomenick J.P., Saville B.R., Wang W., Buchowski M.S., Cone R.D. Energy expenditure in obese children with pseudohypoparathyroidism type 1a. Int J Obes (Lond) 2013, 37:1147-1153.
174. Carel J.C., Le Stunff C., Condamine L., Mallet E., Chaussain J.L., Adnot P., et al. Resistance to the lipolytic action of epinephrine: a new feature of protein Gs deficiency. J Clin Endocrinol Metab 1999, 84:4127-4131.
175. Nwosu B.U., Lee M.M. Pseudohypoparathyroidism type 1a and insulin resistance in a child. Nat Rev Endocrinol 2009, 5:345-350.
176. Bates A.S., Farrell W.E., Bicknell E.J., McNicol A.M., Talbot A.J., Broome J.C., et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997, 82:818-824.
177. Green A., Gasic S., Milligan G., Dobias S.B. Increased concentrations of proteins Gi1 and Gi2 in adipocytes from aged rats alter the sensitivity of adenylyl cyclase to inhibitory and stimulatory agonists. Metabolism 1995, 44:239-244.
178. Gardella T.J., Luck M.D., Fan M.H., Lee C. Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J Biol Chem 1996, 271:12820-12825.
179. Vlaeminck-Guillem V., D'Herbomez M., Pigny P., Fayard A., Bauters C., Decoulx M., et al. Pseudohypoparathyroidism Ia and hypercalcitoninemia. J Clin Endocrinol Metab 2001, 86:3091-3096.
180. Faull C.M., Welbury R.R., Paul B., Kendall-Taylor P. Pseudo-hypoparathyroidism: its phenotypic variability and associated disorders in a large family. Q J Med 1991, 78:251-264.
181. Weinstein L.S., Gejman P.V., Friedman E., Kadowaki T., Collins R.M., Gershon E.S., et al. Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1990, 87:8287-8290.
182. Croft L.K., Witkop C.J., Glas J.E. Pseudohypoparathyroidism. Oral SurgOral Med Oral Pathol 1965, 20:758-770.
183. Joseph A.W., Shoemaker A.H., Germain-Lee E.L. Increased prevalence of carpal tunnel syndrome in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 2011, 96:2065-2073.
184. Poznanski A.K., Werder E.A., Giedion A., Martin A., Shaw H. The pattern of shortening of the bones of the hand in PHP and PPHP-a comparison with brachydactyly E, Turner syndrome, and acrodysostosis. Radiology 1977, 123:707-718.
185. Graudal N., Galloe A., Christensen H., Olesen K. The pattern of shortened hand and foot bones in D- and E-brachydactyly and pseudohypoparathyroidism/pseudopseudohypoparathyroidism. ROFO Fortschr Geb Rontgenstr Nuklearmed 1988, 148:460-462.
186. Linglart A., Menguy C., Couvineau A., Auzan C., Gunes Y., Cancel M., et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011, 364:2218-2226.
187. Michot C., Le Goff C., Goldenberg A., Abhyankar A., Klein C., Kinning E., et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet 2012, 90:740-745.
188. Rump P., Jongbloed J.D., Sikkema-Raddatz B., Mundlos S., Klopocki E., van der Luijt R.B. Madelung deformity in a girl with a novel and de novo mutation in the GNAS gene. Am J Med Genet A 2011, 155A:2566-2570.
189. Steinbach H.L., Rudhe U., Jonsson M., Young D.A. Evolution of skeletal lesions in pseudohypoparathyroidism. Radiology 1965, 85:670-676.
190. Alam S.M., Kelly W. Spinal cord compression associated with pseudohypoparathyroidism. J R Soc Med 1990, 83:50-51.
191. Pollard A.J., Prendergast M., al-Hammouri F., Rayner P.H., Shaw N.J. Different subtypes of pseudohypoparathyroidism in the same family with an unusual psychiatric presentation of the index case. Arch Dis Child 1994, 70:99-102.
192. Izraeli S., Metzker A., Horev G., Karmi D., Merlob P., Farfel Z. Albright hereditary osteodystrophy with hypothyroidism, normocalcemia, and normal Gs protein activity. Am J Med 1992, 43:764-767.
193. Cairns D.M., Pignolo R.J., Uchimura T., Brennan T.A., Lindborg C.M., Xu M., et al. Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasia. J Clin Invest 2013, 123:3624-3633.
194. Pignolo R.J., Xu M., Russell E., Richardson A., Kaplan J., Billings P.C., et al. Heterozygous inactivation of Gnas in adipose-derived mesenchymal progenitor cells enhances osteoblast differentiation and promotes heterotopic ossification. J Bone Miner Res 2011, 26:2647-2655.
195. Lietman S.A., Ding C., Cooke D.W., Levine M.A. Reduction in Gsalpha induces osteogenic differentiation in human mesenchymal stem cells. Clin Orthop Relat Res 2005, 434:231-238.
196. Rios C.N., Skoracki R.J., Mathur A.B. GNAS1 and PHD2 short-interfering RNA support bone regeneration in vitro and in an in vivo sheep model. Clin Orthop Relat Res 2012, 470:2541-2553.
197. Huso D.L., Edie S., Levine M.A., Schwindinger W., Wang Y., Juppner H., et al. Heterotopic ossifications in a mouse model of Albright hereditary osteodystrophy. PLoS One 2011, 6. 21755.
198. Regard J.B., Malhotra D., Gvozdenovic-Jeremic J., Josey M., Chen M., Weinstein L.S., et al. Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat Med 2013, 19:1505-1512.
199. Moses A.M., Rao K.J., Coulson R., Miller R. Parathyroid hormone deficiency with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1974, 39:496-500.
200. Isozaki O., Sato K., Tsushima T., Shizume K., Takamatsu J. A patient of short stature with idiopathic hypoparathyroidism, round face and metacarpal signs. Endocrinol Jpn 1984, 31:363-367.
201. Le Roith D., Burshell A.C., Ilia R., Glick S.M. Short metacarpal in a patient with idiopathic hypoparathyroidism. Israel J Med Sci 1979, 15:460-461.
202. Moses A.M., Notman D.D. Albright's osteodystrophy in a patient with renal hypercalciuria. J Clin Endocrinol Metab 1979, 49:794-797.
203. Sasaki H., Tsutsu N., Asano T., Yamamoto T., Kikuchi M., Okumura M. Co-existing primary hyperparathyroidism and Albright's hereditary osteodystrophy-an unusual association. Postgrad Med J 1985, 61:153-155.
204. Wilson L.C., Leverton K., Oude Luttikhuis M.E., Oley C.A., Flint J., Wolstenholme J., et al. Brachydactyly and mental retardation: an Albright hereditary osteodystrophy-like syndrome localized to 2q37. Am J Hum Genet 1995, 56:400-407.
205. Phelan M.C., Rogers R.C., Clarkson K.B., Bowyer F.P., Levine M.A., Estabrooks L.L., et al. Albright hereditary osteodystrophy and del(2)(q37.3) in four unrelated individuals. Am J Med Genet 1995, 58:1-7.
206. Tsang R.C., Venkataraman P., Ho M., Steichen J.J., Whitsett J., Greer F. The development of pseudohypoparathyroidism. Am J Dis Child 1984, 138:654-658.
207. Barr D.G., Stirling H.F., Darling J.A. Evolution of pseudohypoparathyroidism: an informative family study. Arch Dis Child 1994, 70:337-338.
208. Neary N.M., El-Maouche D., Hopkins R., Libutti S.K., Moses A.M., Weinstein L.S. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab 2012, 97:3025-3030.
209. Burnstein M.I., Kottamasu S.R., Pettifor J.M., Sochett E., Ellis B.I., Frame B. Metabolic bone disease in pseudohypoparathyroidism: radiologic features. Radiol J 1985, 155:351-356.
210. Long D.N., Levine M.A., Germain-Lee E.L. Bone mineral density in pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2010, 95:4465-4475.
211. Sbrocchi A.M., Rauch F., Lawson M.L., Hadjiyannakis S., Lawrence S., Bastepe M., et al. Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis. Eur J Endocrinol 2011, 164:295-301.
212. Wehbi V.L., Stevenson H.P., Feinstein T.N., Calero G., Romero G., Vilardaga J.P. Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gbetagamma complex. Proc Natl Acad Sci USA 2013, 110:1530-1535.
213. Wan M., Yang C., Li J., Wu X., Yuan H., Ma H., et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 2008, 22:2968-2979.
214. Dabbaugh S., Chesney R.W., Langer L.O., DeLuca H.F., Gilbert E.F., DeWeerd J.H. Renal-non-responsive, bone-responsive pseudohypoparathyroidism. A case with normal vitamin D metabolite levels and clinical features of rickets. Am J Dis Child 1984, 138:1030-1033.
215. Hall F.M., Segall-Blank M., Genant H.K., Kolb F.O., Hawes L.E. Pseudohypoparathyroidism presenting as renal osteodystrophy. Skeletal Radiol 1981, 6:43-46.
216. Breslau N.A., Moses A.M., Pak C.Y.C. Evidence for bone remodeling but lack of calcium mobilization response to parathyroid hormone in pseudohypoparathyroidism. J Clin Endocrinol Metab 1983, 57:638-644.
217. Weinstock R.S., Wright H.N., Spiegel A.M., Levine M.A., Moses A.M. Olfactory dysfunction in humans with deficient guanine nucleo-tide binding protein. Nature 1986, 322:635-636.
218. Henkin R.I. Impairment of olfaction and of the tastes of sour and bitter in pseudohypoparathyroidism. J Clin Endocrinol Metab 1968, 28:624-628.
219. Koch T., Lehnhardt E., Bottinger H., Pfeuffer T., Palm D., Fischer B., et al. Sensorineural hearing loss owing to deficient G proteins in patients with pseudohypoparathyroidism: results of a multicentre study. Eur J Clin Invest 1990, 20:416-421.
220. Lerea C.L., Somers D.E., Hurley J.B., Klock I.B., Bunt Milam A.H. Identification of specific transducin alpha subunits in retinal rod and cone photoreceptors. Science 1986, 234:77-80.
221. Lochrie M.A., Hurley J.B., Simon M.I. Sequence of the alpha subunit of photoreceptor G protein: homologies between transducin, ras, and elongation factors. Science 1985, 228:96-99.
222. Jones D.T., Reed R.R. Golf: an olfactory neuron specific-G protein involved in odorant signal transduction. Science 1989, 244:790-795.
223. McLaughlin S.K., McKinnon P.J., Margolskee R.F. Gustducin is a taste-cell specific G protein closely related to the transducins. Nature 1992, 357:563-568.
224. Sklar P.B., Anholt R.R.H., Snyder S.H. The odorant-sensitive adenylate cyclase of olfactory receptor cells. J Biol Chem 1986, 261:15538-15543.
225. Pace U., Hanski E., Salomon Y., Lancet D. Odorant-sensitive adenylate cyclase may mediate olfactory reception. Nature 1985, 316:255-258.
226. Pace U., Lancet D. Olfactory GTP-binding protein: signal-transducing |polypeptide of vertebrate chemosensory neurons. Proc Natl Acad Sci USA 1986, 83:4947-4951.
227. Ikeda K., Sakurada T., Sasaki Y., Takasaka T., Furukawa Y. Clinical investigation of olfactory and auditory function in type I pseudohypoparathyroidism: participation of adenylate cyclase system. J Laryngol Otol 1988, 102:1111-1114.
228. Doty R.L., Fernandez A.D., Levine M.A., Moses A., McKeown D.A. Olfactory dysfunction in type I pseudohypoparathyroidism: dissociation from Gs alpha protein deficiency. J Clin Endocrinol Metab 1997, 82:247-250.
229. Bakalyar H.A., Reed R.R. Identification of a specialized adenylyl cyclase that may mediate odorant detection. Science 1990, 250:1403-1406.
230. Jackowski M.M., Hannon D., Sturr J.F., Moses A.M. Enhanced contrast sensitivity in patients with pseudohypoparathyroidism 1992, Program of the Annual Meeting of ARVO, Abstract 1371-20:966.
231. Mouallem M., Shaharabany M., Weintrob N., Shalitin S., Nagelberg N., Shapira H., et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol (Oxf) 2008, 68:233-239.
232. Farfel Z., Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med 1986, 105:197-199.
233. Faig J.C., Kalinyak J., Marcus R., Feldman D. Chronic atypical seizure disorder and cataracts due to delayed diagnosis of pseudohypoparathyroidism. West J Med 1992, 157:64-65.
234. Bonadio W.A. Hypocalcemia caused by pseudohypoparathyroidism presenting as convulsion. Pediatr Emerg Care 1989, 5:22-23.
235. Furukawa T. Periodic psychosis associated with pseudo-pseudohypoparathyroidism. J Nerv Ment Dis 1991, 179:637-638.
236. Klawans H.L., Lupton M., Simon L. Calcification of the basal ganglia as a cause of levodopa-resistant parkinsonism. Neurology 1976, 26:221-225.
237. Dure L.S., Mussell H.G. Paroxysmal dyskinesia in a patient with pseudohypoparathyroidism. Mov Disord 1998, 13:746-748.
238. Vaamonde J., Legarda I., Jimenez-Jimenez J., Zubieta J.L., Obeso J.A. Levodopa-responsive parkinsonism associated with basal ganglia calcification and primary hypoparathyroidism. Mov Disord 1993, 8:398-400.
239. Uncini A., Tartaro A., Di Stefano E., Gambi D. Parkinsonism, basal ganglia calcification and epilepsy as late complications of postoperative hypoparathyroidism. J Neurol 1985, 232:109-111.
240. Tambyah P.A., Ong B.K., Lee K.O. Reversible parkinsonism and asymptomatic hypocalcemia with basal ganglia calcification from hypoparathyroidism 26 years after thyroid surgery. Am J Med 1993, 94:444-445.
241. Hamilton D.V. Familial pseudohypoparathyroidism presenting in adult life. J R Soc Med 1980, 73:724-726.
242. Litvin Y., Rosler A., Bloom R.A. Extensive cerebral calcification in hypoparathyroidism. Neuroradiology 1981, 21:271-272.
243. Sachs C., Sjoberg H.E., Ericson K. Basal ganglia calcifications on CT: relation to hypoparathyroidism. Neurology 1982, 32:779-782.
244. Korn-Lubetzki I., Rubinger D., Siew F. Visualization of basal ganglion calcification by cranial computed tomography in a patient with pseudohypoparathyroidism. Israel J Med Sci 1980, 16:40-41.
245. Pearson D.W.M., Durward W.F., Fogelman I., Boyle I.T., Beastall G. Pseudohypoparathyroidism presenting as severe Parkinsonism. Postgrad Med J 1981, 57:445-447.
246. Levine M.A., Jap T.S., Hung W. Infantile hypothyroidism in two sibs: an unusual presentation of pseudohypoparathyroidism type Ia. J Pediatr 1985, 107:919-922.
247. Miano A., Casadel G., Biasini G. Cardiac failure in pseudo-hypoparathyroidism. Helv Paediatr Acta 1981, 36:191-192.
248. Cavallo A., Meyer W.J., Bodensteiner J.B., Chesson A.L. Spinal cord compression: an unusual manifestation of pseudohypoparathyroidism. Am J Dis Child 1980, 134:706-707.
249. Breslau N.A., Notman D., Canterbury J.M., Moses A.M. Studies on the attainment of normocalcemia in patients with pseudohypoparathyroidism. Am J Med 1980, 68:856-860.
250. Lindsay R., Nieves J., Henneman E., Shen V., Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993, 77:1535-1539.
251. Stirling H.F., Darling J.A., Barr D.G. Plasma cyclic AMP response to intravenous parathyroid hormone in pseudohypoparathyroidism. Acta Paediatr Scand 1991, 80:333-338.
252. Furlong T.J., Seshadri M.S., Wilkinson M.R., Cornish C.J., Luttrell B., Posen S. Clinical experiences with human parathyroid hormone 1-34. Aust NZ J Med 1986, 16:794-798.
253. Sohn H.E., Furukawa Y., Yumita S., Miura R., Unakami H., Yoshinaga K. Effect of synthetic 1-34 fragment of human parathyroid hormone on plasma adenosine 3', 5'-monophosphate (cAMP) concentrations and the diagnostic criteria based on the plasma cAMP response in Ellsworth-Howard test. Endocrinol Jpn 1984, 31:33-40.
254. Miura R., Yumita S., Yoshinaga K., Furukawa Y. Response of plasma 1,25-dihydroxyvitamin D in the human PTH(1- 34) infusion test: an improved index for the diagnosis of idiopathic hypoparathyroidism and pseudohypoparathyroidism. Calcif Tissue Int 1990, 46:309-313.
255. McElduff A., Lissner D., Wilkinson M., Cornish C., Posen S.A. 6-hour human parathyroid hormone (1-34) infusion protocol: studies in normal and hypoparathyroid subjects. Calcif Tissue Int 1987, 41:267-273.
256. Lebowitz M.R., Moses A.M. Hypocalcemia. Semin Nephrol 1992, 12:146-158.
257. Litvak J., Moldawer M.P., Forbes A.P., Henneman P.H. Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism. J Clin Endocrinol Metab 1958, 18:246-252.
258. Yamamoto M., Takuwa Y., Masuko S., Ogata E. Effects of endogenous and exogenous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism. J Clin Endocrinol Metab 1988, 66:618-625.
259. Okano K., Furukawa Y., Morii H., Fujita T. Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. J Clin Endocrinol Metab 1982, 55:238-243.
260. Breslau N.A., Zerwekh J.E. Relationship of estrogen and pregnancy to calcium homeostasis in pseudohypoparathyroidism. J Clin Endocrinol Metab 1986, 62:45-51.
261. Verbeelen D., Fuss M. Hypercalcemia induced by estrogen withdrawal in vitamin D-treated hypoparathyroidism. BM J 1979, 1:522-523.
262. Mallette L.E. Case report: hypoparathyrodisim with menses-associated hypocalcemia. Am J Med Sci 1992, 304:32-37.
263. Singh A., Agarwal N., Chopra S., Sikka P., Suri V., Kumar B., et al. Management of Pseudohypoparathyroidism type 1a during pregnancy and labor: a case report. Case Rep Obstet Gynecol 2012, 2012:629583.
264. O'Donnell D., Costa J., Meyers A.M. Management of pseudohypoparathyroidism in pregnancy. Case report. Br J Obstet Gynaecol 1985, 92:639-641.
265. Zerwekh J.E., Breslau N.A. Human placental production of 1 alpha,25-dihydroxyvitamin D3: biochemical characterization and production in normal subjects and patients with pseudohypoparathyroidism. J Clin Endocrinol Metab 1986, 62:192-196.
266. Kovacs C.S. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinol Metab Clin North Am 2011, 40:795-826.
267. Firooznia H., Golimbu C., Rafii M. Progressive paraparesis in a woman with pseudohypoparathyroidism with ossification of the posterior longitudinal ligament from C4 to T5. Skelatal Radiol 1985, 13:310-313.
268. Levine M.A., Jap T.S., Mauseth R.S., Downs R.W., Spiegel A.M. Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine, and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 1986, 62:497-502.
269. Mallette L.E., Kirkland J.L., Gagel R.F., Law W.M., Heath H. Synthetic human parathyroid hormone-(1-34) for the study of pseudohypoparathyroidism. J Clin Endocrinol Metab 1988, 67:964-972.
270. Levine M.A., Parfrey N.A., Feinstein R.S. Pseudohypoparathyroidism. The Johns Hopkins Med J 1982, 151:137-146.